Reviewing Amgen (NASDAQ:AMGN) & CASI Pharmaceuticals (NASDAQ:CASI)

CASI Pharmaceuticals (NASDAQ:CASI) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for CASI Pharmaceuticals and Amgen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CASI Pharmaceuticals 0 0 1 0 3.00
Amgen 0 8 11 0 2.58

CASI Pharmaceuticals presently has a consensus price target of $7.00, indicating a potential upside of 118.07%. Amgen has a consensus price target of $223.50, indicating a potential downside of 4.39%. Given CASI Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe CASI Pharmaceuticals is more favorable than Amgen.

Insider and Institutional Ownership

11.3% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 76.6% of Amgen shares are held by institutional investors. 24.3% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares CASI Pharmaceuticals and Amgen’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CASI Pharmaceuticals N/A N/A -$27.47 million ($0.32) -10.03
Amgen $23.75 billion 5.85 $8.39 billion $14.40 16.23

Amgen has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

CASI Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Amgen has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Profitability

This table compares CASI Pharmaceuticals and Amgen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CASI Pharmaceuticals N/A -38.08% -31.00%
Amgen 34.48% 80.26% 14.50%

Summary

Amgen beats CASI Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Amgen Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit